CERA

unofficial impact factor 1.46
Search for
Advanced search
Cost Effectiveness and Resource Allocation
Tools
Share this article
Open Access Email this article to a friend

Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands

Gijs AA Hubben*, Jasper M Bos, Christa A Veltman-Starkenburg, Simon Stegmeijer, Henrik W Finnern, Bregt S Kappelhoff, Kit N Simpson, Andrea Tramarin and Maarten J Postma

Cost Effectiveness and Resource Allocation 2007, 5:15 doi:10.1186/1478-7547-5-15

Fields marked * are required


Multiple email addresses should be separated with commas or semicolons.